| Literature DB >> 35447123 |
Mary Carol Burkhardt1, Francis J Real2, Dominick DeBlasio2, Andrew F Beck3, Allison Reyner4, Brittany L Rosen5.
Abstract
Pediatric primary care is a trusted source for treatment and information. In the 6 months after coronavirus disease 2019 vaccines became available for adolescents, we administered 2286 doses (1270 to patients; 1016 to household members) to 1376 individuals (64.1% Black; 10.1% Latinx), providing opportunities to address family concerns in a familiar location.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35447123 PMCID: PMC9014639 DOI: 10.1016/j.jpeds.2022.04.023
Source DB: PubMed Journal: J Pediatr ISSN: 0022-3476 Impact factor: 6.314
Descriptive results and demographics of persons receiving COVID-19 vaccine in primary care
| Categories | Patients (n = 746) | Household members (n = 630) | Totals (n = 1376) |
|---|---|---|---|
| Doses of vaccine given | 1270 | 1016 | 2286 |
| Vaccines given during | |||
| Routine care | 570 (44.9%) | 0 (0%) | 570 (24.9%) |
| Vaccine-only visit | 700 (55.1%) | 1016 (100%) | 1716 (75.1%) |
| Demographics | |||
| Age range, y | 12-20 | 12-81 | 12-81 |
| Race | |||
| Black/African American | 551 (73.9%) | 331 (52.5%) | 882 (64.1%) |
| White and others | 195 (26.1%) | 299 (47.5%) | 494 (35.9%) |
| Ethnicity | |||
| Latinx | 73 (9.8%) | 77 (12.2%) | 150 (10.9%) |
| Non-Latinx | 673 (90.2%) | 553 (87.8%) | 1226 (89.1%) |
| Insurance | |||
| Public | 606 (81.2%) | 332 (52.7%) | 938 (68.2%) |
| Private | 121 (16.2%) | 136 (21.6%) | 257 (18.7%) |
| Self-pay/none | 19 (2.6%) | 162 (25.7%) | 181 (13.1%) |
FigureCOVID-19 vaccines administered per week and age of recipient.
Patient/caregiver reported reasons for influencing COVID-19 vaccine acceptance
| Influencing factors | % (n = 427) |
|---|---|
| Studies/data supporting vaccination | 12.4% (53) |
| Concerns of contracting new variants | 5.2% (22) |
| Parent/family member | 32.3% (138) |
| Friends | 0.7% (3) |
| Medical provider | 8.4% (36) |
| Media outlet | 0% (0) |
| Family/friend/self had COVID-19 | 1.6% (7) |
| Other | 16.6% (71) |
| N/A—second or third dose | 11.5% (49) |
N/A, not applicable.